黄葵胶囊联合替米沙坦治疗早中期糖尿病肾病疗效观察

目的探讨黄葵胶囊联合替米沙坦综合治疗糖尿病肾病的临床疗效。方法将80例糖尿病肾病患者随机分为治疗组（42例）和对照组（38例），均给予控制饮食、血糖、血脂等基础治疗；对照组给予替米沙坦口服，治疗组在对照组治疗基础上加用黄葵胶囊，疗程3个月。观察两组治疗前后尿微量白蛋白（mAlb）、24h尿蛋白定量（24hUpr）、血肌酐（Scr）、血尿素氮（BUN）等指标的变化。结果治疗3个月后，治疗组总有效率85.71%，对照组65.79%，差异有统计学意义（P〈0.05）；两组mAlb、Upro、Scr、BUN均明显下降（P〈0.05），且治疗组尿蛋白下降幅度优于对照组（P〈0.05）。结论黄葵胶囊可提高糖尿病肾病患者临床疗效，有效降低尿蛋白、保护肾功能。

Objective To explore the clinical efficacy of Okra Capsule combined with telmisartan for early metaphase diabetic nephropathy. Methods Eighty subjects were randomized into two groups：control group in which 38 cases were treated by telmisartan and conventional therapy,and treatment group in which 42 cases were treated with Okra Capsule and western conventional therapy, with a course of 3 months. The blood serum,urea nitrogen,24h urine albumin,microalbuminuria were observed before and after treatment. Results After treatment ,there was statistical differences between treatment group was higher than that of control group in the total effective rate. The blood serum,urea nitrogen,24h urine albumin,microalbuminuria in both groups were improved （P〈0.05）. urinary albumin in treatment group decreased significantly（P〈0.05）. Conclusion Okra capsule can improve clinical efficacy of DN and reduce urinary albumin to prevent diabetic nephropathy.